Navigation Links
Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
Date:5/6/2013

nfectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development and Janssen Biotech are part of the Janssen Pharmaceutical Companies. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
9. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
10. Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
11. CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster Expanded Lab Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- CARsgen, a leader in the development of Chimeric Antigen ... of cancers, today announced the completion of a series ... -based healthcare private equity fund.   ... of new therapeutics for liver, lung, stomach and brain ... Renji Hospital, the company plans to initiate clinical studies ...
(Date:11/26/2014)... According to the new ... (Electric, Battery, Pneumatic), by Product (Drill, Saw, Stapler, ... Application (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global ... Surgical Instruments Market is estimated to be worth ... is expected to grow at a moderate CAGR ...
(Date:11/26/2014)... YORK , Nov. 25, 2014  Medtronic,s ... Covidien has been widely discussed in the ... it,s also creating a stronger leading player in ... to Kalorama Information.  The healthcare market research firm ... systems will feature a diverse set of solutions ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
(Date:11/26/2014)... Peoria, Il (PRWEB) November 27, 2014 ... is excited to announce the kick-off of its ... AlignLife encourages people to go to donate to ... will partner with local organizations to distribute the ... December 20th, participating AlignLife locations will be accepting ...
(Date:11/26/2014)... 2014 Recently, DressVe , the ... dresses, has unveiled its 2014 Cyber Monday Sales. Also, ... dresses, up to 90 percent off. The special offer ... Free delivery is provided for orders above $69. , ... shoes, handbags and other fashion accessories. The mission of ...
(Date:11/26/2014)... Boxing Day is traditionally the day following Christmas ... as a "Christmas box", from their bosses or employers. ... of Boxing Day, some people may worry about the ... opportunity, and it has recently announced its “ Tbdress ... its global customers. Then people can buy cheap pants, ...
(Date:11/26/2014)... Norwalk Hospital is pleased to announce ... the American Nurses Credentialing Center (ANCC). , The ... work environments where nurses can flourish. The designation ... Hospital and identifies it as one of the ... organizations’ commitment to nurses and their contributions toward ...
(Date:11/26/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, ... more likely to achieve remission if they maintain a healthy ... that those who were heaviest had almost 65 percent reduced ... of remission. "Medication for rheumatoid arthritis is not as ... study,s lead author and a rheumatologist at the Hospital for ...
Breaking Medicine News(10 mins):Health News:DressVe.com: Best 2014 Special Monday Sales Online 2Health News:Tbdress.com: Best Boxing Day Sales For Ladies Worldwide 2Health News:Norwalk Hospital Announces American Nurses Credentialing Center PATHWAY TO EXCELLENCE® DESIGNATION 2Health News:Norwalk Hospital Announces American Nurses Credentialing Center PATHWAY TO EXCELLENCE® DESIGNATION 3Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3
... (HealthDay News) -- Cancer patients are often faced with ... effects and even mean the difference between life and ... doctors use plain language in explaining the options, ... medicine at the University of Michigan Medical School and ...
... -- The American College of Physicians (ACP) and the ... commend the Centers for Medicare and Medicaid Services on ... "The American College of Physicians believes that the ... the kind of personalized and coordinated care that patients ...
... Wearable sensors that allow the blind to "see" with ... horizon, thanks to a $2 million award from the ... College of New York and Georgia Institute of Technology ... Frontiers in Research and Innovation" program, will fund a ...
... at the University of California, San Francisco (UCSF) Medical Center ... occurs as healthy brain cells begin to form tumors. ... a common type of brain tumor, at its earliest stage, ... will have to prove safe and effective in clinical trials, ...
... prevention trial evaluating two antiretroviral (ARV)-based approaches for preventing the ... one of two different ARV tablets or of a vaginal ... from the study. The decision to discontinue use of tenofovir ... data concluded that the trial will not be able to ...
... of the American Physical Society,s (APS) Division of Fluid ... from across the physical sciences, engineering, and medicine. Topics ... the quirks of flying; why coffee spills; and how ... The meeting will take place November 20-22, ...
Cached Medicine News:Health News:Cancer Patients Should Ask Doctors to Use Simple Terms 2Health News:Consumers and physicians together applaud Comprehensive Primary Care Initiative 2Health News:City College of New York-led research could lead to wearable sensors for the blind 2Health News:City College of New York-led research could lead to wearable sensors for the blind 3Health News:How normal cells become brain cancers 2Health News:Major HIV prevention trial in women to drop oral tenofovir arm 2Health News:Major HIV prevention trial in women to drop oral tenofovir arm 3Health News:Major HIV prevention trial in women to drop oral tenofovir arm 4Health News:Major HIV prevention trial in women to drop oral tenofovir arm 5Health News:APS Division of Fluid Dynamics meeting: Highlights and media registration 2Health News:APS Division of Fluid Dynamics meeting: Highlights and media registration 3Health News:APS Division of Fluid Dynamics meeting: Highlights and media registration 4Health News:APS Division of Fluid Dynamics meeting: Highlights and media registration 5
... opens new windows for the laboratory in ... easily move from one function to another. ... tests, and add a new patient record ... keep track of all the open functions ...
... DxC systems are built to ... laboratory. The systems have ... lab thrive in todays environment. ... workflow interruptions and maximize user-friendliness, ...
... Wedge Suture Anchors are titanium anchors that ... The Wedge anchors are simple to use ... staff. The following sizes and styles are ... Single Eyelet 2 Sutures, 5.0mm Double Eyelet ...
... an absorbable co-polymer synthesized from all-natural ... glycolic acid. Unlike the homopolymers in ... acid (PLLA) or 100% poly-glycolic acid ... (without crystallinity), meaning that its degradation ...
Medicine Products: